{"language":[{"iso":"eng"}],"day":"01","author":[{"last_name":"Dormeshkin","first_name":"Dmitri","full_name":"Dormeshkin, Dmitri"},{"full_name":"Katsin, Mikalai","first_name":"Mikalai","last_name":"Katsin"},{"full_name":"Stegantseva, Maria","last_name":"Stegantseva","first_name":"Maria"},{"full_name":"Golenchenko, Sergey","first_name":"Sergey","last_name":"Golenchenko"},{"first_name":"Michail","last_name":"Shapira","full_name":"Shapira, Michail"},{"full_name":"Dubovik, Simon","last_name":"Dubovik","first_name":"Simon"},{"full_name":"Lutskovich, Dzmitry","first_name":"Dzmitry","last_name":"Lutskovich"},{"last_name":"Kavaleuski","orcid":"0000-0003-2091-526X","first_name":"Anton","id":"62304f89-eb97-11eb-a6c2-8903dd183976","full_name":"Kavaleuski, Anton"},{"first_name":"Alexander","last_name":"Meleshko","full_name":"Meleshko, Alexander"}],"isi":1,"abstract":[{"lang":"eng","text":"The potential of immune-evasive mutation accumulation in the SARS-CoV-2 virus has led to its rapid spread, causing over 600 million confirmed cases and more than 6.5 million confirmed deaths. The huge demand for the rapid development and deployment of low-cost and effective vaccines against emerging variants has renewed interest in DNA vaccine technology. Here, we report the rapid generation and immunological evaluation of novel DNA vaccine candidates against the Wuhan-Hu-1 and Omicron variants based on the RBD protein fused with the Potato virus X coat protein (PVXCP). The delivery of DNA vaccines using electroporation in a two-dose regimen induced high-antibody titers and profound cellular responses in mice. The antibody titers induced against the Omicron variant of the vaccine were sufficient for effective protection against both Omicron and Wuhan-Hu-1 virus infections. The PVXCP protein in the vaccine construct shifted the immune response to the favorable Th1-like type and provided the oligomerization of RBD-PVXCP protein. Naked DNA delivery by needle-free injection allowed us to achieve antibody titers comparable with mRNA-LNP delivery in rabbits. These data identify the RBD-PVXCP DNA vaccine platform as a promising solution for robust and effective SARS-CoV-2 protection, supporting further translational study."}],"oa":1,"year":"2023","quality_controlled":"1","date_published":"2023-06-01T00:00:00Z","volume":11,"scopus_import":"1","article_processing_charge":"No","title":"Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein","intvolume":"        11","citation":{"ista":"Dormeshkin D, Katsin M, Stegantseva M, Golenchenko S, Shapira M, Dubovik S, Lutskovich D, Kavaleuski A, Meleshko A. 2023. Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. Vaccines. 11(6), 1014.","mla":"Dormeshkin, Dmitri, et al. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein.” <i>Vaccines</i>, vol. 11, no. 6, 1014, MDPI, 2023, doi:<a href=\"https://doi.org/10.3390/vaccines11061014\">10.3390/vaccines11061014</a>.","short":"D. Dormeshkin, M. Katsin, M. Stegantseva, S. Golenchenko, M. Shapira, S. Dubovik, D. Lutskovich, A. Kavaleuski, A. Meleshko, Vaccines 11 (2023).","ama":"Dormeshkin D, Katsin M, Stegantseva M, et al. Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. 2023;11(6). doi:<a href=\"https://doi.org/10.3390/vaccines11061014\">10.3390/vaccines11061014</a>","chicago":"Dormeshkin, Dmitri, Mikalai Katsin, Maria Stegantseva, Sergey Golenchenko, Michail Shapira, Simon Dubovik, Dzmitry Lutskovich, Anton Kavaleuski, and Alexander Meleshko. “Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein.” <i>Vaccines</i>. MDPI, 2023. <a href=\"https://doi.org/10.3390/vaccines11061014\">https://doi.org/10.3390/vaccines11061014</a>.","apa":"Dormeshkin, D., Katsin, M., Stegantseva, M., Golenchenko, S., Shapira, M., Dubovik, S., … Meleshko, A. (2023). Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. <i>Vaccines</i>. MDPI. <a href=\"https://doi.org/10.3390/vaccines11061014\">https://doi.org/10.3390/vaccines11061014</a>","ieee":"D. Dormeshkin <i>et al.</i>, “Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein,” <i>Vaccines</i>, vol. 11, no. 6. MDPI, 2023."},"ddc":["570"],"publication_identifier":{"eissn":["2076-393X"]},"has_accepted_license":"1","tmp":{"name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)","legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode","short":"CC BY (4.0)","image":"/images/cc_by.png"},"article_number":"1014","publication":"Vaccines","issue":"6","month":"06","date_created":"2023-07-16T22:01:10Z","publication_status":"published","license":"https://creativecommons.org/licenses/by/4.0/","publisher":"MDPI","external_id":{"isi":["001017740000001"]},"status":"public","article_type":"original","_id":"13232","file":[{"checksum":"8f484c0f30f8699c589b1c29a0fd7d7f","file_name":"2023_Vaccines_Dormeshkin.pdf","file_id":"13244","relation":"main_file","content_type":"application/pdf","file_size":2339746,"creator":"dernst","access_level":"open_access","date_updated":"2023-07-18T07:25:43Z","success":1,"date_created":"2023-07-18T07:25:43Z"}],"file_date_updated":"2023-07-18T07:25:43Z","acknowledgement":"The authors declare that this study received funding from Immunofusion. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The authors express their gratitude to the Institute of Physiology of the National Academy of Sciences of Belarus for providing assistance in keeping laboratory animals.","doi":"10.3390/vaccines11061014","department":[{"_id":"LeSa"}],"oa_version":"Published Version","user_id":"4359f0d1-fa6c-11eb-b949-802e58b17ae8","type":"journal_article","date_updated":"2023-08-02T06:31:19Z"}